Overview of studies included in the systematic review for gastrointestinal primaries
| Author, year | Study type | Primary | Patient | SRT | Systemic therapy | Non-target response | Criteria |
|---|---|---|---|---|---|---|---|
| Chino et al. [59], 2018 | Case report | HCC | 58*, M | 60 Gy/8 fx to primary NSCLC | None | CR of both primaries | No systemic treatment |
| Nakabori et al. [60], 2024 | Case report | HCC | 60*, M | 35 Gy/5 fx | Bevacizumab (discontinued during SRT) + atezolizumab | CR of a lung mtx at 4 months, PR on primary at 2 months | Better response after SBRT |
| Zhao et al. [61], 2018 | Case report | Esophageal | 66*, M | 42 Gy/6 fx on L retroperitoneal node | Previous CHT, concomitant pembrolizumab | CR after 2 months of massive pelvis nodes | PD under IT |
| Hai et al. [62], 2024 | Case report | Esophageal | 64*, M | 45 Gy/5 fx to 2 lung mtxs | Anti-PD-L1 camrelizumab | PR/CR of other lung mtxs at 1 months. 34 months PF | PD-1 neg |
| Kim and Kim [63], 2019 | Case report | NSCLC/ICC | 70*, M | 42 Gy/4 fx to lung primary | Previous palliative CHT (gemcitabine and cisplatin ×8) | CR at 3.3 months of a 5 cm liver metastasis | No concomitant systemic treatment |
| Liu et al. [64], 2019 | Case series | ICC | 52*, F | 55 Gy/5 fx on hepatic hilar N | Concomitant nivolumab | 1 month after PR of hilar and retroperitoneal N, stable at 13 months FUP | PD-1 neg |
| ICC | 59*, M | 52 Gy/4 fx on primary hepatic recurrence | Concomitant pembrolizumab | 1 month after PR of hilar and retroperitoneal N, followed by CR, PD at 5 months when IT was stopped | PD-1 neg | ||
| ICC | 51*, M | 52 Gy/4 fx on L hepatic lobe recurrence and L retroperitoneal N | Concomitant pembrolizumab | 1 month after, PR on a hilar N, PFS 24 months | PD-1 neg |
HCC: hepatocellular carcinoma; NSCLC: non-small cell lung cancer; ICC: intrahepatic cholangiocarcinoma; M: male; F: female; fx: fraction(s); L: left; mtxs: metastases; N: node/nodal; SRT: stereotactic radiation techniques; CHT: chemotherapy; CR: complete response; mtx: metastasis; PF: progression free; FUP: follow-up; PR: partial response; PD: progression disease; PFS: progression free survival; SBRT: stereotactic body radiotherapy; IT: immunotherapy; neg: negative